Once again, Eli Lilly is using Hollywood ... year’s entertainment awards season, Lilly took aim at the popular off-label use of GLP-1 drugs like its Mounjaro and Zepbound for cosmetic weight ...

Eli Lilly’s profit ... expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity ...

Eli Lilly will spend ... device assembly, and packaging for medicines across multiple therapeutic areas," according to a company statement. Sales of both Mounjaro and Zepbound have been held ...

The Ozempic CKD data, meanwhile, is heading for a final readout next ... candidate for cancer. Lilly’s Mounjaro also growing strongly Also this morning, Eli Lilly reported big sales gains ...

Eli Lilly announced plans Wednesday to invest at least $27 billion in building four new manufacturing plants in the United States, significantly expanding its domestic production capabilities as ...

In late February, Indianapolis-based Eli Lilly made a big splash by announcing ... Sales were up 45% to $13.5 billion, with diabetes drug Mounjaro and weight loss drug Zepbound leading the way.

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. 1. Time and money ...